Clinical Trial Update: Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis [EARLY_Phase 1]

View source ↗

Summary

An EARLY_PHASE1 clinical trial is evaluating the efficacy and safety of a combination of pozelimab and cemdisiran in Sporadic Inclusion Body Myositis and relate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathies
• Sporadic Inclusion Body Myositis

Drugs mentioned

• Cemdisiran (cemdisiran)
• Pozelimab

Snippet

Sponsor: Austin Neuromuscular Center | Conditions: Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies | EARLY_Phase 1 | Status: RECRUITING